SHSongyin Huang

Songyin Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Songyin Huang has a total of 129 co-authors. Here are the top co-authors by number of shared publications:

  • Hongyu Li

    Department of Laboratory, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.

    6 shared publications
  • Xiquan Wu

    Department of Clinical Laboratory, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China

    5 shared publications
  • Baiji Chen

    Department of Laboratory, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China

    4 shared publications
  • Xiaoying Xie

    Department of Laboratory, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China

    4 shared publications
  • Xinlu Dai

    Department of Laboratory, Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China

    4 shared publications
  • Yandan Yao

    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China.

    4 shared publications

Latest Publications

  • Open Access

    BET Inhibition Enhances Chemotherapy-Induced Antitumor Immunity by Limiting Macrophage Recruitment in Triple-Negative Breast Cancer

    by Songyin Huang, Yue Chen, Jiawei Wang, Jueqiong Xu, Yaofeng Zhou, Tengyao Wang, Jiajun Huang, Fuxiang Wang, Huosheng Zhou, Qiang Liu, et al.

    Background Chemotherapy can promote antitumor immunity in part by inducing immunogenic forms of tumor cell death, providing a rationale for combining cytotoxic agents with immunomodulatory therapies. However, chemotherapy-treated tumors may also develop myeloid-dominated microenvironments that restrict effective T cell responses. Here, we investigated whether bromodomain and extraterminal domain inhibition (BETi) could improve the immune response elicited by liposomal doxorubicin (Doxil) in triple-negative breast cancer (TNBC). Methods We evaluated JQ1 combined with Doxil in orthotopic 4T1 and EMT6 TNBC models, with other BET inhibitors and cisplatin used to examine broader applicability. Transcriptomic profiling, flow cytometry, immunofluorescence, and molecular assays characterized immune responses. T cell depletion, nude mice, and tumor rechallenge assessed immune dependence and memory. Macrophage recruitment was investigated using tumor profiling and in vitro migration assays. Results JQ1 enhanced Doxil-mediated tumor control in both models, prolonged survival in 4T1 mice, and induced complete, recurrence-free regression in EMT6 mice following repeated treatment. Additional BET inhibitors also enhanced chemotherapy efficacy. Antitumor benefit was lost in nude mice and attenuated by CD8 + T cell depletion. Combination treatment increased intratumoral T cell infiltration and activation, effector memory responses, granzyme B expression, and tumor apoptosis, while conferring resistance to rechallenge. JQ1 can reduce chemotherapy-associated macrophage accumulation, decreased CD206 and increased CD86 expression, and inhibited macrophage migration toward CCL2 and chemotherapy-treated tumor cells. Conclusions These findings suggest that BETi can improve chemotherapy-induced antitumor immunity by limiting macrophage recruitment and thereby creating a tumor microenvironment more permissive for CD8 + T cell-mediated tumor control.

  • Microbiota-immune crosstalk underlying cancer-induced depression in patients with breast cancer

    by Yuanyuan Li, Baoyuan Zhu, Xiaomei Wu, Lanlan Meng, Songyin Huang, Kai Wu


  • Open Access

    Efficient on-demand cuproptosis induction against triple-negative breast cancer via dual-responsive black phosphorus nanosheet

    by Qiancun Hong, Jiajun Huang, Zhiguo Li, Yue Chen, Jiawei Wang, Tongrui Shang, Zelin Chen, Cong Luo, Yongqiang Wang, Xinghong Tang, et al.


  • Selective recognition of bacterial phospholipids by antimicrobial peptides: Employing a host-guest-mediated competitive inhibition strategy

    by Xinshuang Zhang, Dong Luo, Jie Hu, Kangxiu Wu, Shuyi Jia, Xueyi Li, Songyin Huang, Houbing Zhang, Dokyun Kim, Yuzhi Hong, et al.


  • Open Access

    Helicity-directed recognition of bacterial phospholipid via radially amphiphilic antimicrobial peptides

    by Yangbin Liang, Yuhao Zhang, Yu Huang, Cheng Xu, Jingxian Chen, Xinshuang Zhang, Bingchuan Huang, Zhanhui Gan, Xuehui Dong, Songyin Huang, et al.

    The fundamental differences in phospholipids between bacterial and mammalian cell membranes present remarkable opportunities for antimicrobial design. However, it is challenging to distinguish bacterial anionic phospholipid phosphatidylglycerol (PG) from mammalian anionic phosphatidylserine (PS) with the same net charge. Here, we report a class of radially amphiphilic α helix antimicrobial peptides (RAPs) that can selectively discriminate PG from PS, relying on the helix structure. The representative RAP, L 10 -MMBen, can direct the rearrangement of PG vesicles into a lamellar structure with its helix axis parallel to the PG membrane surface. The helical structure imparts both the thermodynamic and kinetic advantages of L 10 -MMBen/PG assembly, and the hiding of hydrophobic regions in RAPs is crucial for PG recognition. L 10 -MMBen exhibits high selectivity against bacteria depending on PG recognition, showing low in vivo toxicity and significant treatment efficacy in mice infection models. Our study introduces a helicity-direct bacterial phospholipid recognition paradigm for designing highly selective antimicrobial peptides.


  • Open Access

    Directional transport of drug droplets based on structural and wettability gradients on antibacterial Janus wound plaster with hemostatic, antiextravasation, and prehealing properties

    by Jing Lin, Zhen Yao, Minmin Xiong, Jin Lin, Fei Hu, Xinchuan Wei, Songyin Huang

    The failure of wound healing is majorly attributed to uncontrolled bleeding and bacterial infections. However, developing a wound plaster that can stop bleeding, resist blood extravasation, and realize directional transportation of drugs to promote wound healing remains a significant challenge. Herein, a superhydrophilic/hydrophobic polyvinyl alcohol/chitosan/silver@Thermoplastic polyurethane (PVA/CS/Ag@TPU) Janus membrane with structural and wettability gradients is developed. In this newly developed membrane, water is absorbed from blood via the superhydrophilic layer, which is attached to the wound, and the charge interactions between platelets and the introduced chitosan (CS) promote blood clotting. The capillary pressure resistance (∆p > 0) of the superhydrophilic layer toward the hydrophobic layer prevents blood permeation, thereby reducing blood loss. The favorable ∆p (< 0) of the membrane based on its structural and wettability gradients can realize the directional transportation of drugs that promote wound healing from the hydrophobic to the superhydrophilic layer. The incorporation of CS and silver endows the Janus membrane with intrinsic antibacterial properties (99.9%). The formation of the hydrated layer on the hydrophilic layer imparts a resisting effect, further endowing the membrane with antiadhesion and antibacterial properties. Experiments involving mice with full-thickness skin wounds revealed that the wound-healing rate increased from 87.65% to ~ 100% when the Janus membrane was loaded with the prehealing drug. Moreover, the dressing accelerated wound healing, regenerated epidermal and granulation tissues, promoted collagen formation, and reduced scar size. Thus, this gradient design strategy opens an avenue for the development of next-generation wound dressings. Graphical abstract


  • Open Access

    Disinfection Strategies for Carbapenem-Resistant Klebsiella pneumoniae in a Healthcare Facility

    by Lijia Ni, Zhixian Zhang, Rui Shen, Xiaoqiang Liu, Xuexue Li, Baiji Chen, Xiquan Wu, Hongyu Li, Xiaoying Xie, Songyin Huang

    Disinfectant resistance is evolving into a serious problem due to the long-term and extensive use of disinfectants, which brings great challenges to hospital infection control. As a notorious multidrug-resistant bacterium, carbapenem-resistant Klebsiella pneumoniae (CRKP) is one of the most common and difficult pathogens of nosocomial infection. The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) tests of seven kinds of disinfectants (0.1% benzalkonium bromide, 4% aqueous chlorhexidine, 75% alcohol, entoiodine II, 2% glutaraldehyde, 2000 mg/L chlorine-containing disinfectants, and 3% hydrogen peroxide) were detected by the broth dilution method. Three efflux pump genes (oqxA, oqxB, and qacE∆1-sul1) were detected by PCR. The mean MIC value of aqueous chlorhexidine from the intensive care unit (ICU) (0.0034%) was significantly higher than that from non-ICUs (0.0019%) (p < 0.05). The positive rates of three efflux pump genes oqxA, oqxB and qacE∆1-sul1 were 60.9% (39/64), 17.2% (11/64) and 71.9% (46/64) in the detected CRKP isolates, respectively. This study discovered that CRKP strains demonstrated extensive resistance to clinical disinfectants and suggest that it is necessary to perform corresponding increases in the concentration of aqueous chlorhexidine and chlorine-containing disinfectants on the basis of current standards in the healthcare industry.


  • Open Access

    Metagenomic Analyses Reveal Distinct Gut Microbiota Signature for Predicting the Neoadjuvant Chemotherapy Responsiveness in Breast Cancer Patients

    by Yuanyuan Li, Bingbin Dong, Wei Wu, Jiawei Wang, Hao Jin, Kangmei Chen, Kangling Huang, Songyin Huang, Yandan Yao

    Background: Growing evidence supports the modulatory role of human gut microbiome on neoadjuvant chemotherapy (NAC) efficacy. However, the relationships among the gut microbiome, tumor-infiltrating lymphocytes (TILs), and NAC response for breast cancer (BC) patients remain unclear. We thus proposed this preliminary study to investigate the relationship between gut microbiome and BC patients’ responses to NAC treatment as well as underlying mechanisms.Methods: Prior to receiving NAC, the fecal metagenome collected from 23 patients with invasive BC was analyzed. Patients were subsequently assigned to the NAC non-effectual group and the NAC effectual group based on their response to NAC. The peripheral T lymphocyte subset counts were examined by flow cytometry methods. CellMinor analysis was employed to explore the relationship between CD4 mRNA expression and the reaction of tumor cells to NAC drugs.Results: The gut microbiomes of the NAC non-effectual group showed characteristics of low diversity with low abundances, distinct metagenomic composition with decreased butyrate-producing and indolepropionic acid-producing bacteria, and increased potential pathobionts compared with the NAC effectual group. The combination of Coprococcus, Dorea, and uncultured Ruminococcus sp. serves as signature bacteria for distinguishing NAC non-effectual group patients from the NAC effectual group. The absolute numbers of CD4+ and CD8+ TIL infiltration in tumors in the NAC non-effectual group were significantly lower than those in the effectual group. Similar findings were reported for the CD4+ T lymphocytes in the peripheral blood (p’s < 0.05). NAC effectual-related signature bacteria were proportional to these patients’ CD4+ T lymphocyte counts in peripheral blood and tumors (p’s < 0.05). CellMinor analysis showed that the CD4 mRNA expression level dramatically climbed with increased sensitivity of tumor cells to NAC drugs such as cyclophosphamide, cisplatin, and carboplatin (p’s < 0.05).Conclusions: The composition of the gut microbial community differs between BC patients for whom NAC is effective to those that are treatment resistant. The modulation of the gut microbiota on host CD4+ T lymphocytes may be one critical mechanism underlying chemosensitivity and NAC pathologic response. Taken together, gut microbiota may serve as a potential biomarker for NAC response, which sheds light on novel intervention targets in the treatment of NAC non-effectual BC patients.


  • Open Access

    Disinfection Strategies of Carbapenem-resistant Klebsiella Pneumoniae in a Healthcare Facility

    by Lijia Ni, Zhixian Zhang, Rui Shen, Xiaoqiang Liu, Xuexue Li, Baiji Chen, Xiquan Wu, Hongyu Li, Xiaoying Xie, Songyin Huang

    Abstract Background: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections have become a major global public health challenge. Disinfectants play an important role in controlling horizontal transmission in healthcare facilities. However, the long and extensive routine use of disinfectants, and far less regulated, leading to concern about the development of disinfectant resistance. We detected the susceptibility of CRKP strains against seven kinds of disinfectants commonly used in clinic to guide and assist the infection control work in hospital. Methods: The minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) tests of seven kinds of disinfectants (0.1% benzalkonium bromide, 4% aqueous chlorhexidine, 75% alcohol, entoiodine II, 2% glutaraldehyde, 2000mg/L chlorine-containing disinfectants and 3% hydrogen peroxide) were detected by broth dilution method. Three efflux pump genes (oqxA、oqxB、and qacE△1-sul1) were detected by PCR. Results: A total of 162 strains of non-repetitive CRKP strains were isolated in SYS Memorial Hospital from 2015 to 2019. The MBCs expressed by diluted multiples of 64 CRKP strains against the seven kinds of disinfectants were 1-128, 16-32768, 2-64, 16-4096, 4-64, 2-8 and 64-2048, respectively. Aqueous chlorhexidine should be ≥ 2.5 g/L when rinsing or gargling mucous membrane and wound, 0.1% benzalkonium bromide should avoided be diluted, and chlorine-containing disinfectants should be ≥ 1000 mg/L. The mean MIC value of aqueous chlorhexidine from intensive care unit (ICU) (0.0034%) was significantly higher than that from non-ICU (0.0019%) (p < 0.05). The positive rates of three efflux pump genes oqxA, oqxB and qacE△1-sul1 were 68.8% (44/64), 15.6% (10/64) and 89.1% (57/64), respectively.Conclusion: The CRKP strains isolated showed extensive resistance to clinically used disinfectants, and the concentration of aqueous chlorhexidine and chlorine-containing disinfectants needs to be increased compared with the current standards of the healthcare industry. It reminds us to strengthen the monitoring of disinfectant resistance to super drug-resistant bacteria.


  • Open Access

    Advanced Glycation End Products Enhance Biofilm Formation by Promoting Extracellular DNA Release Through sigB Upregulation in Staphylococcus aureus

    by Xiaoying Xie, Xiaoqiang Liu, Yanling Li, Ling Luo, Wenchang Yuan, Baiji Chen, Guoyan Liang, Rui Shen, Hongyu Li, Songyin Huang, et al.

    Bacterial biofilms do serious harm to the diabetic foot ulcer (DFU) because they play a crucial role in infection invasion and spread. Staphylococcus aureus, the predominant Gram-positive bacteria in diabetic foot infection (DFI), is often associated with colonization and biofilm formation. Through biofilm formation tests in vitro, we observed that S. aureus bacteria isolated from DFU wounds were more prone to form biofilms than those from non-diabetic patients, while there was no difference in blood sugar between the biofilm (+) diabetics (DB+) and biofilm (-) diabetics (DB-). Furthermore, we found that advanced glycation end products (AGEs) promoted the biofilm formation of S. aureus in clinical isolates and laboratory strains in vitro, including a methicillin-resistant strain. Analysis of biofilm components demonstrated that the biofilms formed mainly by increasing extracellular DNA (eDNA) release; remarkably, the S. aureus global regulator sigB was upregulated, and its downstream factor lrgA was downregulated after AGE treatments. Mechanism studies using a sigB-deleted mutant (Newman-ΔsigB) confirmed that AGEs decreased expression of lrgA via induction of sigB, which is responsible for eDNA release and is a required component for S. aureus biofilm development. In conclusion, the present study suggests that AGEs promote S. aureus biofilm formation via an eDNA-dependent pathway by regulating sigB. The data generated by this study will provide experimental proof and theoretical support to improve DFU infection healing.